TO THE EDITOR
The mitogen-activated protein kinase signaling pathway plays an important role in cell proliferation, differentiation and survival and is frequently altered in cancer. Genetic mechanisms that activate the mitogen-activated proteinkinase pathway vary among subtypes of melanoma when tumors are classified according to a combination of sun exposure and anatomic site (Maldonado et al., 2003; Curtin et al., 2005 Curtin et al., , 2006 . NRAS (neuroblastoma ras viral oncogene homolog), which is part of the RAS/RAF/mitogen-activated proteinkinase signaling cascade, is mutated in 10-20% of melanomas regardless of anatomic site. In contrast, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are frequent (about 60%) in melanomas occurring on skin without signs of chronic sun-induced damage (CSD) (non-CSD melanomas), but infrequent in melanomas that occur on skin showing evidence of CSD as well as on sun-protected skin such as the palms, soles, or subungual sites (acral melanomas), and on mucosal membranes (mucosal melanomas) (Maldonado et al., 2003; Curtin et al., 2005) . We have recently reported increased copy numbers of chromosome 4q12 and identified v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) as a somatic target that is activated in CSD, acral, and mucosal melanoma. This genomic region contains several additional genes that are involved in other types of cancer, including the platelet-derived growth factor a receptor (PDGFRA). PDGFRA is a receptor tyrosine kinase, which is activated by mutations or small deletions in a subset of gastrointestinal stroma tumors (Heinrich et al., 2003b) and childhood acute myeloid leukaemia's (Hiwatari et al., 2005) as well as fusion with FIP1L1 in hypereosinophilic syndrome (Cools et al., 2003) and systemic mastocytosis associated with eosinophilia (Pardanani et al., 2003) . Mutation of PDGFRA or KIT occurs infrequently in most solid tumors with the exception of gastrointestinal stroma tumors (Sihto et al., 2005) . In gastrointestinal stroma tumors, mutations in PDGFRA and KIT are mutually exclusive (Heinrich et al., 2003a, b) and tumors with either mutation can show responses with kinase inhibitors such as imatinib, dasatinib, and sunitinib (Heinrich et al., 2003a; Corless et al., 2006; Schittenhelm et al., 2006) . PDGFRA has been found to be overexpressed in some melanomas (Barnhill et al., 1996) , raising the possibility that it could also be a target of somatic mutations in some melanomas. To date, a limited mutation analysis of primary tumors did not find mutations in PDGFRA (Curtin et al., 2006) . To address fully the role of PDGFRA in melanoma, we analyzed a larger set of primary melanomas for mutations, copy number increases, and expression of PDGFRA. To increase the likelihood of encountering mutations, we enriched the samples for cases that did not have mutations of KIT or BRAF.
Specifically, we analyzed DNA extracted from archival paraffin-embedded primary melanomas with an invasive component in which tumor cells predominated over stroma cells. Additional analyses on some of these cases were reported previously (Curtin et al., 2005 (Curtin et al., , 2006 . Institutional Review Board of the University of California, San Francisco, approved the study. From a cohort of 102, we sequenced the 26 primary melanomas which had increased copy number of the 4q12 locus harboring PDGFRA (n ¼ 10) or had normal copy number but did not show mutations in KIT exons 11, 13, 17, and 18, and BRAF exon 15 (n ¼ 16). Seven of the cases were acral melanomas, that is melanomas from the palms, soles, and subungual sites; 13 were mucosal melanomas; and three were melanomas from chronically sundamaged skin, and three melanoma from skin without chronic sun damage. CSD was defined by the microscopic presence or absence of marked solar elastosis of the dermis surrounding the melanomas. Exons of interest were amplified by PCR and sequenced as described previously (Curtin et al., 2005) using specific primers flanking the common (Heinrich et al., 2003b) mutation sites of PDGFRA; exons 10, 12, 14, and 18 (Table S1 ). No mutations of PDGFRA were found in any or our melanoma samples. Our samples contained a majority of tumor cells, which excludes the possibility that mutations were missed owing to an excess of stromal cells. In addition, all samples included in this analysis showed DNA copy number changes by CGH (Curtin et al., 2005 (Curtin et al., , 2006 , which indicates that Abbreviations: CSD, chronic sun damage; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; NRAS, neuroblastoma ras viral oncogene homolog; PDGFRA, platelet-derived growth factor a receptor the DNA was extracted from a sufficiently pure, clonally related tumor cell population. It should also be noted that over a third of our samples had multiple copies of the 4q12 locus. These copy number increases are expected to affect selectively any mutated allele as we have demonstrated previously for KIT (Curtin et al., 2006) and BRAF (Maldonado et al., 2003) . The increased dosage of the mutated allele allows the detection of such mutations even in a significant excess of normal cells. We cannot exclude the possibility that undetected mutations may be present in a minority of cells; however, the relevance of such mutations would be unclear as these cells would not have been clonally selected. In situ hybridization for PDGFRA mRNA was performed on 14 samples with adequate residual sample. Increased PDGFRA expression was observed in 5/14 samples, but was not linked to increased copy number of the 4q12 locus (Table  S2 ). The absence of PDGFRA mutations in melanomas with and without increased copy number of 4q12 in melanomas without other known mitogen-activated protein kinase abnormalities, together with our previous observation that KIT mutations are commonly found in melanomas of the acral, mucosal and CSD types, suggests that KIT and not PDGFRA is the relevant gene in melanoma that drives the selection of copy number increases of the locus. Whether the increased expression of PDGFRA that occurs in some melanomas can be exploited therapeutically needs to be shown.
